
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc is positioned favorably within the expanding COVID-19 vaccine market, which saw revenues of approximately $56 billion in 2022, reflecting a substantial opportunity for growth. The company's VYD2311 has received FDA approval for a pivotal Phase 3 program (REVOLUTION) that may enhance its market potential and establish its monoclonal antibodies' superiority over conventional mRNA vaccines. With innovative design features such as half-life extension technology and optimized biophysical characteristics, Invivyd aims to capture a significant share of a projected $3-4 billion global market by 2030.
Bears say
Invivyd Inc is facing significant challenges in its product efficacy, particularly highlighted by the STAMP trial results, which revealed that the activity of its candidate against the omicron variant was reduced by approximately 200-fold compared to earlier expectations. Furthermore, there are concerning trends regarding declining vaccination rates for COVID-19 and influenza, which indicate that the overall market opportunity for antibody-based treatments is shrinking, especially among vulnerable populations such as the elderly and immunocompromised individuals. These factors, combined with misleading initial modeling results, contribute to a negative outlook on the company's stock prospects and its ability to capitalize on its antibody developments.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares